UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049967
Receipt number R000056911
Scientific Title Multi-institutional clinical study of patients with major depressive disorder and healthy participants to examine the usefulness of the brain network marker program using fMRI for the diagnosis and stratification of major depressive disorder
Date of disclosure of the study information 2023/03/24
Last modified on 2023/12/08 17:42:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multi-institutional clinical study of patients with major depressive disorder and healthy participants to examine the usefulness of the brain network marker program using fMRI for the diagnosis and stratification of major depressive disorder

Acronym

Multi-institutional clinical study to examine the usefulness of the brain network marker program using fMRI for the diagnosis of major depressive disorder

Scientific Title

Multi-institutional clinical study of patients with major depressive disorder and healthy participants to examine the usefulness of the brain network marker program using fMRI for the diagnosis and stratification of major depressive disorder

Scientific Title:Acronym

Multi-institutional clinical study to examine the usefulness of the brain network marker program using fMRI for the diagnosis of major depressive disorder

Region

Japan


Condition

Condition

Patients with major depressive disorder and healthy participants

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The usefulness of the "diagnostic brain network marker" and "stratification brain network marker" for major depressive disorder calculated from fMRI images by the AI program will be verified using clinical data anterogradely.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

AUC of ROC curves in discriminating between depressed and healthy groups calculated using depression diagnostic brain network markers

Key secondary outcomes

-Diagnostic brain network markers for major depressive disorder evaluated longitudinally (0w, 6w, 6m).
-Depression severity (Hamilton Rating Scale for Depression) obtained longitudinally (0w, 6w) in the usual care group.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

[Patients]
(1)Men and women aged between 20 and 75 at the time of consent acquisition.
(2)Patients with major depressive disorder using structured diagnostic interview measured after obtaining the consent.
(3)Patients who provide written and voluntary consent for participation in this study.
[Healthy participants]
(1)Men and women aged between 20 and 75 at the time of consent acquisition.
(2)Those whose psychiatric diagnostic interview results measured after obtaining consent are not psychiatric disorders.
(3)Participants who provide written and voluntary consent for participation in this study.

Key exclusion criteria

[Patients]
(1)Patients with mental status that makes it difficult to understand the purpose of the study.
(2)Patients who meet any of the following criteria:
-Patients with depression with psychotic features.
-Patients who have been diagnosed with bipolar disorder or schizophrenia using DSM.
-Patients who have been diagnosed with substance abuse within 6 months prior to obtaining consent.
-Patients who have been treated for an anxiety disorder within 6 months prior to obtaining consent.
-Patient who have a comorbid personality disorder at the time of consent acquisition.
(3)Patients with significant suicidal tendencies.
(4)Patients with contraindications to MRI.
(5)Patients who are deemed inappropriate as research participants by the principal investigator or a subinvestigator.
[Healthy participants]
(1)Participants with current or history of psychiatric or neurological disorders.
(2)Participants with contraindications to MRI.
(3)Participants who are deemed inappropriate as research participants by the principal investigator or a subinvestigator.

Target sample size

520


Research contact person

Name of lead principal investigator

1st name Hidehiko
Middle name
Last name Takahashi

Organization

Tokyo Medical and Dental University

Division name

Department of Psychiatry and Behavioral Sciences

Zip code

1138510

Address

1-5-45 Yushima, Bunkyo-ku, Tokyo

TEL

03-5803-5238

Email

hidepsyc@tmd.ac.jp


Public contact

Name of contact person

1st name Junya
Middle name
Last name Fujino

Organization

Tokyo Medical and Dental University

Division name

Department of Psychiatry and Behavioral Sciences

Zip code

1138510

Address

1-5-45 Yushima, Bunkyo-ku, Tokyo

TEL

03-5803-5238

Homepage URL


Email

jf15psyc@tmd.ac.jp


Sponsor or person

Institute

Tokyo Medical and Dental University

Institute

Department

Personal name



Funding Source

Organization

XNef Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokyo Medical and Dental University Ethics Review Committee, School of Medicine

Address

1-5-45 Yushima, Bunkyo-ku, Tokyo

Tel

03-3813-6111

Email

syomu1.adm@tmd.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京医科歯科大学病院(東京都)、東京大学医学部附属病院(東京都)、昭和大学発達障害医療研究所(東京都)、慶應義塾大学病院(東京都)、国立精神・神経医療研究センター病院(東京都)


Other administrative information

Date of disclosure of the study information

2023 Year 03 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2023 Year 01 Month 25 Day

Date of IRB

2023 Year 03 Month 06 Day

Anticipated trial start date

2023 Year 06 Month 22 Day

Last follow-up date

2025 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Observational Study


Management information

Registered date

2023 Year 01 Month 05 Day

Last modified on

2023 Year 12 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056911


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name